{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T20:24:27Z","timestamp":1770668667532,"version":"3.49.0"},"reference-count":13,"publisher":"Georg Thieme Verlag KG","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n          Fragestellung Mit dem Lippst\u00e4dter Benzo-Check k\u00f6nnen\n                    (Langzeit-) Anwendern von Benzodiazepinen und Z-Substanzen\n                    \u00fcberpr\u00fcfen, ob bei ihnen Nebenwirkungen der Langzeiteinnahme\n                    aufgetreten sind. Diese Studie dient der ersten \u00dcberpr\u00fcfung, ob\n                    der Benzo-Check bei einer Gruppe von Benzodiazepin- und\n                    Z-Substanzen-Abh\u00e4ngigen vor Beginn des Entzuges die entsprechenden\n                    Symptome ausreichend erfasst und andererseits eine depressive Kontrollgruppe\n                    ohne Einnahme der entsprechenden Substanzen unauff\u00e4llige Werte\n                    erzielt.<\/jats:p><jats:p>\n          Methode 101 station\u00e4re Entzugspatienten mit Abh\u00e4ngigkeit\n                    von Benzodiazepinen bzw. Z-Substanzen und 154 tagesklinische Patienten ohne die\n                    Einnahme von Benzodiazepinen oder Z-Substanzen f\u00fcllten zu Beginn der\n                    jeweiligen Behandlung den Lippst\u00e4dter Benzo-Check aus. Die Gesamtscores\n                    bzw. die Subscores \u201eAbh\u00e4ngigkeit\u201c wurden zwischen beiden\n                    Gruppen verglichen.<\/jats:p><jats:p>\n          Ergebnisse Die Mittelwerte der Gesamtscores der Benzo-Checks in den beiden\n                    Kollektiven unterscheiden sich hochsignifikant, trotzdem sind rund die\n                    H\u00e4lfte der depressiven Patienten im untersten von drei Warnbereichen\n                    \u2013 \u201eDie von Ihnen angegebenen Symptome kommen wahrscheinlich von\n                    der Langzeiteinnahme der Medikamente\u201c.<\/jats:p><jats:p>Allerdings k\u00f6nnen die Items \u201eSchlafst\u00f6rung\u201c,\n                    \u201eHeimlichkeit\u201c, \u201eWirkverlust\u201c,\n                    \u201eFixierung auf Medikation\u201c und\n                    \u201eIndikationserweiterung\u201c zu einem Subscore\n                    (\u201eAbh\u00e4ngigkeits-Score\u201c) zusammengefasst werden, der eine\n                    hohe Trennsch\u00e4rfe f\u00fcr einen Cut-off-Wert von&lt;5 Punkten\n                    erreicht, da 100% der depressiven Patienten und lediglich 10%\n                    der Entzugs-Patienten darunter liegen.<\/jats:p><jats:p>\n          Schlussfolgerungen Die Ergebnisse dieser ersten Studie mit dem\n                    Lippst\u00e4dter Benzo-Check als Screening-Instrument f\u00fcr\n                    unerw\u00fcnschte Folgen einer Langzeiteinnahme von Benzodiazepinen oder\n                    Z-Substanzen sind ermutigend, trotz methodischer Limitierungen und der\n                    Notwendigkeit f\u00fcr weitere Untersuchungen.<\/jats:p>","DOI":"10.1055\/a-1510-8425","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T22:38:07Z","timestamp":1628894287000},"page":"547-551","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation des Lippst\u00e4dter Benzo-Checks als\n                    Screening-Instrument f\u00fcr Nebenwirkungen der Langzeiteinnahme von\n                    Benzodiazepinen und Z-Substanzen"],"prefix":"10.1055","volume":"89","author":[{"given":"R\u00fcdiger","family":"Holzbach","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Psychiatrie, Psychotherapie und Psychosomatik,\n                    Klinikum Hochsauerland, Arnsberg"},{"name":"Zentrum f\u00fcr Interdisziplin\u00e4re Suchtforschung,\n                    Universit\u00e4tsklinikum Hamburg-Eppendorf, Hamburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Hunold","sequence":"additional","affiliation":[{"name":"LWL-Klinik Lippstadt, Lippstadt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Konert","sequence":"additional","affiliation":[{"name":"LWL-Klinik Lippstadt, Lippstadt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"ref1","first-page":"134","article-title":"Statt low-dose oder Sucht \u2013 Das 5-Phasen-Modell des\n                    Benzodiazepin-Langzeitgebrauchs","volume":"60","author":"R Holzbach","year":"2014","journal-title":"Sucht"},{"key":"ref2","first-page":"64","article-title":"Indikationen f\u00fcr die Langzeitverschreibung von Benzodiazepinen und\n                    Z-Drugs","volume":"19","author":"R Holzbach","year":"2017","journal-title":"Suchtmedizin"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000491879","article-title":"Benzodiazepine Use and Long-Term Mortality in Real-Life Chronic Heart Failure\n                    Outpatients: A Cohort Analysis","volume":"87","author":"C Diez-Quevedo","year":"2018","journal-title":"Psychother Psychosom"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000493015","article-title":"Benzodiazepines: A Valuable Tool in the Management of Cardiovascular\n                    Conditions","volume":"87","author":"R Balon","year":"2018","journal-title":"Psychother Psychosom"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000486696","article-title":"Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic\n                    Review","volume":"87","author":"G Benasi","year":"2018","journal-title":"Psychother Psychosom"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1192\/bjp.169.3.276","article-title":"The Benzodiazepine Dependence Questionnaire: Development, Reliability and\n                    Validity","volume":"169","author":"A J Baillie","year":"1996","journal-title":"British Journal of Psychiatry"},{"key":"ref8","volume-title":"Ratgeber f\u00fcr Medikamentenabh\u00e4ngige und ihre\n                    Angeh\u00f6rigen","author":"W Poser","year":"1985"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0010-440X(99)90129-3","article-title":"Scalability, Reliability and Validity oft he Benzodiazepine Dependence\n                    Self-Report Questionnaire in Outpatient Benzodiazepines Users","volume":"40","author":"C C Kan","year":"1999","journal-title":"Compr Psychiatry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-2007-1017414","article-title":"Verschiedene Schritte der Konstruktvalidierung des Basler Drogen- und\n                    Alkoholfragebogens (BDA)","volume":"17","author":"P Graw","year":"1984","journal-title":"Pharmacopsychiatrie"},{"key":"ref11","first-page":"123","volume-title":"Entwicklung eines Fragebogens zur Erfassung von Medikamentenmi\u00dfbrauch\n                    bei Suchtpatienten. Impulsreferat zur Schwerpunktgruppe:\n                    \u201cMedikamentenkonsum bei psychosomatischen St\u00f6rungen: Therapie -\n                    Mi\u00dfbrauch \u2013 Abh\u00e4ngigkeit\u201d","author":"H Watzl","year":"1991"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00103-010-1029-8","article-title":"Zusammenhang zwischen Verschreibungsverhalten der \u00c4rzte und\n                    Medikamentenabh\u00e4ngigkeit ihrer Patienten","volume":"53","author":"R Holzbach","year":"2010","journal-title":"Bundesgesundheitsblatt"},{"key":"ref13","first-page":"430","article-title":"Langzeitverschreibung von Benzodiazepinen und Non-Benzodiazepinen \u2013 eine\n                    prospektive Analyse \u00fcber 12 Monate","volume":"7","author":"U Verthein","year":"2013","journal-title":"Gesundheitswesen"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00103-017-2571-4","article-title":"Der Gebrauch von Medikamenten mit Abh\u00e4ngigkeitspotenzial in Deutschland\n                    \u2013 Eine prospektive Analyse kassen\u00e4rztlicher Verschreibungen der\n                    Jahre 2006 bis 2010","volume":"60","author":"S Buth","year":"2017","journal-title":"Bundesgesundheitsblatt"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1510-8425.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T23:57:19Z","timestamp":1636156639000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1510-8425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":13,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,5]]},"published-print":{"date-parts":[[2021,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1510-8425","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]}}}